A highly potent extended half-life antibody as a potential rsv vaccine surrogate for all infants

Science Translational Medicine

Volumn 9, Issue 388, 2017, Pages

  Zhu, Qing ^a   McLellan, Jason S ^b   Kallewaard, Nicole L ^a   Ulbrandt, Nancy D ^a   Palaszynski, Susan ^a   Zhang, Jing ^a   Moldt, Brian ^a   Khan, Anis ^a   Svabek, Catherine ^a   McAuliffe, Josephine M ^a   Wrapp, Daniel ^b   Patel, Nita K ^a   Cook, Kimberly E ^a   Richter, Bettina W M ^a   Ryan, Patricia C ^a   Yuan, Andy Q ^a   Suzich, Joann A ^a  

^a MEDIMMUNE   (United States)

^b DARTMOUTH MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; MEDI 8897; MONOCLONAL ANTIBODY; PALIVIZUMAB; RESPIRATORY SYNCYTIAL VIRUS VACCINE; UNCLASSIFIED DRUG; VIRUS FUSION PROTEIN; ANTIVIRUS AGENT;

AMINO ACID SUBSTITUTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING SITE; CONTROLLED STUDY; CRYSTAL STRUCTURE; CRYSTALLOGRAPHY; DRUG BINDING; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENCY; HUMAN; HUMAN RESPIRATORY SYNCYTIAL VIRUS; HUMAN RESPIRATORY SYNCYTIAL VIRUS A; IC50; INFANT; INFECTION PREVENTION; MACACA FASCICULARIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN CONFORMATION; RAT; RESPIRATORY SYNCYTIAL VIRUS B; RESPIRATORY SYNCYTIAL VIRUS INFECTION; SINGLE DRUG DOSE; VIRUS LOAD; VIRUS STRAIN; DRUG EFFECTS; FEMALE; MALE; NEWBORN; PATHOGENICITY; PNEUMOVIRUS;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIVIRAL AGENTS; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; MALE; PALIVIZUMAB; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUS VACCINES; RESPIRATORY SYNCYTIAL VIRUSES;

EID: 85019187653     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.aaj1928     Document Type: Article

References (50)

1. C. B. Hall, G. A. Weinberg, M. K. Iwane, A. K. Blumkin, K. M. Edwards, M. A. Staat, P. Auinger, M. R. Griffin, K. A. Poehling, D. Erdman, C. G. Grijalva, Y. Zhu, P. Szilagyi, The burden of respiratory syncytial virus infection in young children. N. Engl. J. Med. 360, 588-598 (2009).
2. H. Nair, D. J. Nokes, B. D. Gessner, M. Dherani, S. A. Madhi, R. J. Singleton, K. L. O'Brien, A. Roca, P. F. Wright, N. Bruce, A. Chandran, E. Theodoratou, A. Sutanto, E. R. Sedyaningsih, M. Ngama, P. K. Munywoki, C. Kartasasmita, E. A. F. Simõ, I. Rudan, M. W. Weber, H. Campbell, Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: A systematic review and meta-analysis. Lancet 375, 1545-1555 (2010).
3. D. K. Shay, R. C. Holman, R. D. Newman, L. L. Liu, J. W. Stout, L. J. Anderson, Bronchiolitis-associated hospitalizations among US children, 1980-1996. JAMA 282, 1440-1446 (1999).
4. K. N. Carroll, T. Gebretsadik, M. R. Griffin, P. Wu, W. D. Dupont, E. F. Mitchel, R. Enriquez, T. V. Hartert, Increasing burden and risk factors for bronchiolitis-related medical visits in infants enrolled in a state health care insurance plan. Pediatrics 122, 58-64 (2008).
5. L. C. Paramore, P. J. Mahadevia, P. A. Piedra, Outpatient RSV lower respiratory infections among high-risk infants and other pediatric populations. Pediatr. Pulmonol. 45, 578-584 (2010).
6. K. N. Carroll, P. Wu, T. Gebretsadik, M. R. Griffin, W. D. Dupont, E. F. Mitchel, T. V. Hartert, The severity-dependent relationship of infant bronchiolitis on the risk and morbidity of early childhood asthma. J. Allergy Clin. Immunol. 123, 1055-1061.e1 (2009).
7. J. E. Gern, L. A. Rosenthal, R. L. Sorkness, R. F. Lemanske Jr., Effects of viral respiratory infections on lung development and childhood asthma. J. Allergy Clin. Immunol. 115, 668-674 (2005).
8. E. G. Pérez-Yarza, A. Moreno, P. Lázaro, A. Mejías, O. Ramilo, The association between respiratory syncytial virus infection and the development of childhood asthma: A systematic review of the literature. Pediatr. Infect. Dis. J. 26, 733-739 (2007).
9. N. Sigurs, P. M. Gustafsson, R. Bjarnason, F. Lundberg, S. Schmidt, F. Sigurbergsson, B. Kjellman, Severe respiratory syncytial virus bronchiolitis in infancy and asthma and allergy at age 13. Am. J. Respir. Crit. Care Med. 171, 137-141 (2005).
10. S. F. Thomsen, S. van der Sluis, L. G. Stensballe, D. Posthuma, A. Skytthe, K. O. Kyvik, D. L. Duffy, V. Backer, H. Bisgaard, Exploring the association between severe respiratory syncytial virus infection and asthma: A registry-based twin study. Am. J. Respir. Crit. Care Med. 179, 1091-1097 (2009).
11. C. B. Hall, G. A. Weinberg, A. K. Blumkin, K. M. Edwards, M. A. Staat, A. F. Schultz, K. A. Poehling, P. G. Szilagyi, M. R. Griffin, J. V. Williams, Y. Zhu, C. G. Grijalva, M. M. Prill, M. K. Iwane, Respiratory syncytial virus-associated hospitalizations among children less than 24 months of age. Pediatrics 132, e341-e348 (2013).
12. H. Zhou, W. W. Thompson, C. G. Viboud, C. M. Ringholz, P.-Y. Cheng, C. Steiner, G. R. Abedi, L. J. Anderson, L. Brammer, D. K. Shay, Hospitalizations associated with influenza and respiratory syncytial virus in the United States, 1993-2008. Clin. Infect. Dis. 54, 1427-1436 (2012).
13. H. W. Kim, J. G. Canchola, C. D. Brandt, G. Pyles, R. M. Chanock, K. Jensen, R. H. Parrott, Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am. J. Epidemiol. 89, 422-434 (1969).
14. R. S. Tang, R. R. Spaete, M. W. Thompson, M. MacPhail, J. M. Guzzetta, P. C. Ryan, K. Reisinger, P. Chandler, M. Hilty, R. E. Walker, M. M. Gomez, G. A. Losonsky, Development of a PIV-vectored RSV vaccine: Preclinical evaluation of safety, toxicity, and enhanced disease and initial clinical testing in healthy adults. Vaccine 26, 6373-6382 (2008).
15. P. F. Wright, R. A. Karron, R. B. Belshe, J. R. Shi, V. B. Randolph, P. L. Collins, A. F. O'Shea, W. C. Gruber, B. R. Murphy, The absence of enhanced disease with wild type respiratory syncytial virus infection occurring after receipt of live, attenuated, respiratory syncytial virus vaccines. Vaccine 25, 7372-7378 (2007).
16. R. B. Belshe, K. M. Edwards, T. Vesikari, S. V. Black, R. E. Walker, M. Hultquist, G. Kemble, E. M. Connor; CAIV-T Comparative Efficacy Study Group, Live attenuated versus inactivated influenza vaccine in infants and young children. N. Engl. J. Med. 356, 685-696 (2007).
17. C. Luongo, L. Yang, C. C. Winter, K. M. Spann, B. R. Murphy, P. L. Collins, U. J. Buchholz, Codon stabilization analysis of the "248" temperature sensitive mutation for increased phenotypic stability of respiratory syncytial virus vaccine candidates. Vaccine 27, 5667-5676 (2009).
18. A. Chang, R. E. Dutch, Paramyxovirus fusion and entry: Multiple paths to a common end. Viruses 4, 613-636 (2012).
19. M. Magro, V. Mas, K. Chappell, M. Vázquez, O. Cano, D. Luque, M. C. Terrón, J. A. Melero, C. Palomo, Neutralizing antibodies against the preactive form of respiratory syncytial virus fusion protein offer unique possibilities for clinical intervention. Proc. Natl. Acad. Sci. U. S. A. 109, 3089-3094 (2012).
20. The IMpact-RSV Study Group, Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 102, 531-537 (1998).
21. D. Corti, S. Bianchi, F. Vanzetta, A. Minola, L. Perez, G. Agatic, B. Guarino, C. Silacci, J. Marcandalli, B. J. Marsland, A. Piralla, E. Percivalle, F. Sallusto, F. Baldanti, A. Lanzavecchia, Cross-neutralization of four paramyxoviruses by a human monoclonal antibody. Nature 501, 439-443 (2013).
22. M. J. Kwakkenbos, S. A. Diehl, E. Yasuda, A. Q. Bakker, C. M. M. van Geelen, M. V. Lukens, G. M. van Bleek, M. N. Widjojoatmodjo, W. M. J. M. Bogers, H. Mei, A. Radbruch, F. A. Scheeren, H. Spits, T. Beaumont, Generation of stable monoclonal antibody-producing B cell receptor-positive human memory B cells by genetic programming. Nat. Med. 16, 123-128 (2010).
23. W. F. Dall'Acqua, P. A. Kiener, H. Wu, Properties of human IgG1s engineered for enhanced binding to the neonatal Fc receptor (FcRn). J. Biol. Chem. 281, 23514-23524 (2006).
24. W. F. Dall'Acqua, R. M. Woods, E. S. Ward, S. R. Palaszynski, N. K. Patel, Y. A. Brewah, H. Wu, P. A. Kiener, S. Langermann, Increasing the affinity of a human IgG1 for the neonatal Fc receptor: Biological consequences. J. Immunol. 169, 5171-5180 (2002).
25. G. J. Robbie, R. Criste, W. F. Dall'Acqua, K. Jensen, N. K. Patel, G. A. Losonsky, M. P. Griffin, A novel investigational Fc-modified humanized monoclonal antibody, motavizumab-YTE, has an extended half-life in healthy adults. Antimicrob. Agents Chemother. 57, 6147-6153 (2013).
26. G. J. Robbie, L. Zhao, J. Mondick, G. Losonsky, L. K. Roskos, Population pharmacokinetics of palivizumab, a humanized anti-respiratory syncytial virus monoclonal antibody, in adults and children. Antimicrob. Agents Chemother. 56, 4927-4936 (2012).
27. J. S. McLellan, M. Chen, M. G. Joyce, M. Sastry, G. B. E. Stewart-Jones, Y. Yang, B. Zhang, L. Chen, S. Srivatsan, A. Zheng, T. Zhou, K. W. Graepel, A. Kumar, S. Moin, J. C. Boyington, G.-Y. Chuang, C. Soto, U. Baxa, A. Q. Bakker, H. Spits, T. Beaumont, Z. Zheng, N. Xia, S.-Y. Ko, J.-P. Todd, S. Rao, B. S. Graham, P. D. Kwong, Structure-based design of a fusion glycoprotein vaccine for respiratory syncytial virus. Science 342, 592-598 (2013).
28. J. S. McLellan, M. Chen, S. Leung, K. W. Graepel, X. Du, Y. Yang, T. Zhou, U. Baxa, E. Yasuda, T. Beaumont, A. Kumar, K. Modjarrad, Z. Zheng, M. Zhao, N. Xia, P. D. Kwong, B. S. Graham, Structure of RSV fusion glycoprotein trimer bound to a prefusion-specific neutralizing antibody. Science 340, 1113-1117 (2013).
29. S. Johnson, C. Oliver, G. A. Prince, V. G. Hemming, D. S. Pfarr, S.-C. Wang, M. Dormitzer, J. O'Grady, S. Koenig, J. K. Tamura, R. Woods, G. Bansal, D. Couchenour, E. Tsao, W. C. Hall, J. F. Young, Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus. J. Infect. Dis. 176, 1215-1224 (1997).
30. T. F. Feltes, A. K. Cabalka, H. C. Meissner, F. M. Piazza, D. A. Carlin, F. H. Top Jr., E. M. Connor, H. M. Sondheimer; Cardiac Synagis Study Group, Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. J. Pediatr. 143, 532-540 (2003).
31. K. N. Siva Subramanian, L. E. Weisman, T. Rhodes, R. Ariagno, P. J. Sánchez, J. Steichen, L. B. Givner, T. L. Jennings, F. H. Top Jr., D. Carlin, E. Connor, Safety, tolerance and pharmacokinetics of a humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. Pediatr. Infect. Dis. J. 17, 110-115 (1998).
32. G. M. Glenn, L. F. Fries, G. Smith, E. Kpamegan, H. Lu, M. Guebre-Xabier, S. P. Hickman, D. Flyer, Modeling maternal fetal RSV F vaccine induced antibody transfer in guinea pigs. Vaccine 33, 6488-6492 (2015).
33. C. Blattner, J. H. Lee, K. Sliepen, R. Derking, E. Falkowska, A. T. de la Peña, A. Cupo, J.-P. Julien, M. van Gils, P. S. Lee, W. Peng, J. C. Paulson, P. Poignard, D. R. Burton, J. P. Moore, R. W. Sanders, I. A. Wilson, A. B. Ward, Structural delineation of a quaternary, cleavage-dependent epitope at the gp41-gp120 interface on intact HIV-1 Env trimers. Immunity 40, 669-680 (2014).
34. B. Gigant, C. Barbey-Martin, T. Bizebard, D. Fleury, R. Daniels, J. J. Skehel, M. Knossow, A neutralizing antibody Fab-influenza haemagglutinin complex with an unprecedented 2:1 stoichiometry: Characterization and crystallization. Acta Crystallogr. D Biol. Crystallogr. 56, 1067-1069 (2000).
35. J. O. Ngwuta, M. Chen, K. Modjarrad, M. G. Joyce, M. Kanekiyo, A. Kumar, H. M. Yassine, S. M. Moin, A. M. Killikelly, G.-Y. Chuang, A. Druz, I. S. Georgiev, E. J. Rundlet, M. Sastry, G. B. E. Stewart-Jones, Y. Yang, B. Zhang, M. C. Nason, C. Capella, M. E. Peeples, J. E. Ledgerwood, J. S. McLellan, P. D. Kwong, B. S. Graham, Prefusion F-specific antibodies determine the magnitude of RSV neutralizing activity in human sera. Sci. Transl. Med. 7, 309ra162 (2015).
36. A. Hiatt, N. Bohorova, O. Bohorov, C. Goodman, D. Kim, M. H. Pauly, J. Velasco, K. J. Whaley, P. A. Piedra, B. E. Gilbert, L. Zeitlin, Glycan variants of a respiratory syncytial virus antibody with enhanced effector function and in vivo efficacy. Proc. Natl. Acad. Sci. U. S. A. 111, 5992-5997 (2014).
37. M. P. Griffin, A. A. Khan, M. T. Esser, K. Jensen, T. Takas, M. K. Kankam, T. Villafana, F. Dubovsky, Safety, tolerability, and pharmacokinetics of MEDI8897, the respiratory syncytial virus prefusion F-targeting monoclonal antibody with an extended half-life, in healthy adults. Antimicrob. Agents Chemother. 61, e01714-16 (2017).
38. K. Chapman, N. Pullen, L. Coney, M. Dempster, L. Andrews, J. Bajramovic, P. Baldrick, L. Buckley, A. Jacobs, G. Hale, C. Green, I. Ragan, V. Robinson, Preclinical development of monoclonal antibodies: Considerations for the use of non-human primates. MAbs 1, 505-516 (2009).
39. H. Wu, D. S. Pfarr, Y. Tang, L.-L. An, N. K. Patel, J. D. Watkins, W. D. Huse, P. A. Kiener, J. F. Young, Ultra-potent antibodies against respiratory syncytial virus: Effects of binding kinetics and binding valence on viral neutralization. J. Mol. Biol. 350, 126-144 (2005).
40. B. S. Graham, M. D. Perkins, P. F. Wright, D. T. Karzon, Primary respiratory syncytial virus infection in mice. J. Med. Virol. 26, 153-162 (1988).
41. N. D. Ulbrandt, H. Ji, N. K. Patel, J. M. Riggs, Y. A. Brewah, S. Ready, N. E. Donacki, K. Folliot, A. S. Barnes, K. Senthil, S. Wilson, M. Chen, L. Clarke, M. MacPhail, J. Li, R. M. Woods, K. Coelingh, J. L. Reed, M. P. McCarthy, D. S. Pfarr, A. D. M. E. Osterhaus, R. A. M. Fouchier, P. A. Kiener, J. A. Suzich, Isolation and characterization of monoclonal antibodies which neutralize human metapneumovirus in vitro and in vivo. J. Virol. 80, 7799-7806 (2006).
42. Q. Zhu, J. M. McAuliffe, N. K. Patel, F. J. Palmer-Hill, C.-f. Yang, B. Liang, L. Su, W. Zhu, L. Wachter, S. Wilson, R. S. MacGill, S. Krishnan, M. P. McCarthy, G. A. Losonsky, J. A. Suzich, Analysis of respiratory syncytial virus preclinical and clinical variants resistant to neutralization by monoclonal antibodies palivizumab and/or motavizumab. J. Infect. Dis. 203, 674-682 (2011).
43. M. S. A. Gilman, S. M. Moin, V. Mas, M. Chen, N. K. Patel, K. Kramer, Q. Zhu, S. C. Kabeche, A. Kumar, C. Palomo, T. Beaumont, U. Baxa, N. D. Ulbrandt, J. A. Melero, B. S. Graham, J. S. McLellan, Characterization of a prefusion-specific antibody that recognizes a quaternary, cleavage-dependent epitope on the RSV fusion glycoprotein. PLOS Pathog. 11, e1005035 (2015).
44. T. G. G. Battye, L. Kontogiannis, O. Johnson, H. R. Powell, A. G. W. Leslie, iMOSFLM: A new graphical interface for diffraction-image processing with MOSFLM. Acta Crystallogr. D Biol. Crystallogr. 67, 271-281 (2011).
45. P. R. Evans, G. N. Murshudov, How good are my data and what is the resolution? Acta Crystallogr. D Biol. Crystallogr. 69, 1204-1214 (2013).
46. A. J. McCoy, R. W. Grosse-Kunstleve, P. D. Adams, M. D. Winn, L. C. Storoni, R. J. Read, Phaser crystallographic software. J. Appl. Crystallogr. 40, 658-674 (2007).
47. P. Emsley, K. Cowtan, Coot: Model-building tools for molecular graphics. Acta Crystallogr. D Biol. Crystallogr. 60, 2126-2132 (2004).
48. P. D. Adams, R. W. Grosse-Kunstleve, L.-W. Hung, T. R. Ioerger, A. J. McCoy, N. W. Moriarty, R. J. Read, J. C. Sacchettini, N. K. Sauter, T. C. Terwilliger, PHENIX: Building new software for automated crystallographic structure determination. Acta Crystallogr. D Biol. Crystallogr. 58, 1948-1954 (2002).
49. A. Morin, B. Eisenbraun, J. Key, P. C. Sanschagrin, M. A. Timony, M. Ottaviano, P. Sliz, Cutting edge: Collaboration gets the most out of software. eLife 2, e01456 (2013).
50. 11 human antibody repertoire against a broad panel of therapeutically relevant antigens. Protein Eng. Des. Sel. 22, 159-168 (2009).